Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: NASH – the metabolic disease of the liver - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: NASH – the metabolic disease of the liver - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: NASH – the metabolic disease of the liver - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: NASH – the metabolic disease of the liver - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: NASH – the metabolic disease of the liver - Digital ILC 2020
View
Cirrhosis & Complications
6
Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate - The International Liver Congress™ 2019
